OncologyEducation· @OncEd · X·· 18 hours agoScore70
Body · original
Andrew Redfern, MD, on CCTG MA.40/FINER: ipatasertib + fulvestrant kept its PFS benefit but did not improve OS in ER+/HER2− mBC after a CDK4/6 inhibitor. #ESMO26
Watch now: https://bit.ly/4skqDBu
11 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA14matched by Proffered paper 2: Breast cancer, early and advanced stage
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/
https://esmocongress.esmo.orgSource: OncologyEducation · x.com